Sumitomo Mitsui Trust Group Inc. Buys 8,541 Shares of Zoetis Inc. $ZTS

Sumitomo Mitsui Trust Group Inc. boosted its stake in Zoetis Inc. (NYSE:ZTS) by 0.8% in the 2nd quarter, Holdings Channel.com reports. The firm owned 1,054,743 shares of the company’s stock after acquiring an additional 8,541 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Zoetis were worth $164,487,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Sound Income Strategies LLC raised its stake in shares of Zoetis by 54.3% during the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after acquiring an additional 152 shares during the last quarter. Canoe Financial LP raised its stake in shares of Zoetis by 859.0% during the second quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock valued at $2,085,000 after acquiring an additional 11,975 shares during the last quarter. Strs Ohio bought a new position in shares of Zoetis during the first quarter valued at $22,891,000. Tandem Investment Advisors Inc. raised its stake in shares of Zoetis by 100.3% during the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock valued at $65,140,000 after acquiring an additional 198,089 shares during the last quarter. Finally, Soros Capital Management LLC raised its stake in shares of Zoetis by 32.0% during the first quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock valued at $2,872,000 after acquiring an additional 4,230 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.2%

ZTS opened at $146.14 on Friday. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $184.40. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a market cap of $64.77 billion, a P/E ratio of 25.15, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. The company has a fifty day moving average price of $148.18 and a two-hundred day moving average price of $153.50.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s payout ratio is presently 34.42%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ZTS shares. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Friday. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Argus reaffirmed a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Finally, UBS Group decreased their price target on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research note on Monday. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.